Factors affecting the follow-up time after a positive result in the fecal occult blood test

Yin-Wen Cheng¹, Ying-Chun Li²*

¹ Department of Business Management, College of Management, National Sun Yat-Sen University, Kaohsiung, Taiwan, R.O.C, ² Institute of Health Care Management, National Sun Yat-Sen University, Kaohsiung, Taiwan, R.O.C

*ycli@mail.nsysu.edu.tw

Abstract

In 2010, Taiwan included the fecal occult blood test (FOBT) under preventive health insurance services. For patients whose test positive, receiving follow-ups is paramount. This study investigated factors affecting the follow-up time of these patients. This retrospective study used data from the colorectal cancer screening archives. The study period was from 2010 to 2013, and the subjects were 50–75-year-old persons who tested positive for FOBT. The t test, one-way ANOVA, and multiple regression were performed to address the differences in the mean tracking period between variables such as the population's demographic characteristics. The mean follow-up time for the 98,482 participants whose screening results were positive exhibited significant differences (p < 0.001) according to medical unit region and classification, age, screening location, family history, examination method, and diagnosis. The model predicting the mean follow-up time predicted a period of 10.079 days longer for those whose hospital was on an offshore island than that of those whose hospital was in the eastern regions. The follow-up time was 1.257 days shorter for people who were inpatients than those who were outpatients and was 8.902 days longer for people who underwent double contrast barium enema plus flexible sigmoidoscopy than those who underwent other examination methods. Patients with a family history of colorectal cancer and those whose examination results indicated cancer had a follow-up time of 2.562 and 2.476 days shorter than those who did not know their family history and those with other results, respectively. Factors affecting the follow-up time of people whose FOBT results were positive consisted of the location and classification of the follow-up institution, age, screening location, family history, examination method, and diagnosis. This provides valuable references for improving the cancer screening program.

Introduction

Since 1982, the main cause of death in Taiwan has changed from acute diseases to cancer. Among cancers, colorectal cancer (CRC) exhibited the most substantial change. According to the Death Statistics from the Ministry of Health and Welfare and the Cancer Registration Annual Report published in 2018, among the ten most prevalent cancers in Taiwan, the
number of cases of CRC was 16,525, and the age-standardized incidence was 41.84/100,000.
The number of deaths was 5,823, and the age-standardized deaths were 13.78/100,000. CRC
ranked third in the list of causes of death because of cancer [1,2]. The aforementioned data
indicate that CRC is one of the major causes of death and of cancer condition.

According to statistics from the Global Cancer Observatory, in 2020, the number of cases of
CRC worldwide was 1,931,590, and the number of mortalities was 935,173. When the data
were analyzed based on continent and age, the number of CRC cases aged between 50 and 74
years of age was highest in Asia (635,428 cases) followed by Europe (295,645). The number of
CRC mortalities between 50 and 74 years of age was also highest in Asia (269,966 cases) fol-
lowed by Europe (110,338) [3]. Scholars have stated that lifestyle, ethnicity, and genetic factors
affect the incidence of CRC, and these factors lead to large differences in countries worldwide
[4–6]. The aforementioned international statistics and research results reveal that CRC inci-
dence and deaths are closely related to region, ethnicity, and age.

Due to the burden and threat that CRC poses on health, the Cancer Control Act in Taiwan
has, since 2010, included the fecal occult blood test (FOBT) under preventive health care ser-
vices. The method employed is the fecal immunochemical test (FIT), and the recipients are
people aged 50–75 years [7,8]. If the test result is positive, then follow-up examinations should
be arranged. In Israel, the Netherlands, Denmark, Canada, and the United States, the FOBT or
colonoscopy are offered to high-risk groups [9–15]. Clearly, each country values the preven-
tion and treatment of CRC. Currently, Taiwan and other countries consider colonoscopy as an
ideal tool for diagnosis.

A potential problem is that many people testing positive in the FOBT cannot be effectively
traced. Relevant studies have reported that 40%–60% of people who underwent the FOBT and
tested positive could not be traced [16,17]. Another large-scale community study revealed that
people whose FOBT result was positive and who underwent colonoscopy more than 6 months
after the test have an increased risk of CRC-related or terminal diseases [18]. Testing positive
in the FOBT involves possible changes of the disease; thus, identification of factors affecting
the follow-up time are critical [19,20]. Therefore, this study explored factors affecting the fol-
low-up of cases with positive FOBT results to understand why follow-up delays occur.

Recent studies on screening for and following up CRC have mainly adopted insurance data-
base analysis, case review, and questionnaire survey methods [9,19,21–24]. Few health authori-
ties have purposefully established a database for people participating in CRC screening
containing relevant data from across the whole country. Therefore, this study aimed to discuss
the effects of demographic features, cancer screening factors, examination methods, and diag-
nosis results of cases testing positive for FOBT on mean follow-up time. The results may serve
as references for future studies and formulation of cancer prevention policies.

Materials and methods

Research design

A retrospective study design was adopted, and the study period was from 2010 to 2013. The
participants were people first receiving FOBT for preventive health care.

Materials and participants

The database consisted of cancer screening—CRC screening data (H_BHP_CCS) and infor-
mation on health resources of medical facilities (H_OST_RESMF) maintained by the Health
and Welfare Data Science Center of the Ministry of Health and Welfare (HWDC) [25,26]. The
participants were people aged 50–75 years who underwent the FOBT for the first time and
were found to be positive for FOBT. Colorectal cancer screening data includes the following:
1. colorectal cancer screening-general information data (H_BHP_CCS_PD) consisting of data on the population receiving preventive health care that met the criteria for undergoing the FOBT. There were 6,117,581 datasets in the database. 2. FOBT data (H_BHP_CCS_FOB T) consisting of data on the people who actually underwent FOBT, and the screening method used for all subjects was FIT. There were 5,264,818 datasets in the database. 3. colonoscopy report (H_BHP_CCS_CUT) data consisting of data on people with positive FOBT reports who underwent colonoscopy. The number of datasets in the database was 222,683 [25]. Data were reviewed and linked according to the study objective, and their contents are shown in Fig 1. "Positive cases with completed follow-up" were defined as people who tested positive for FOBT and, during the follow-up period, underwent colonoscopy, double contrast barium enema plus flexible sigmoidoscopy, or other recheck methods. "FOBT" refers to the FIT provided under preventive health care services.

Operational definitions of variables

FOBT results were defined as “negative or positive.” Independent variables consisted of the following. Sex was defined as “male or female.” The locations of medical institutions for screening and the follow-up examination were defined as “offshore cities and counties, northern region, central region, southern region, or eastern region” [27]. The age groups that were screened and tested positive were classified as “50, 51–55, 56–60, 61–65, 66–70, and 71–75 years old.” Screening locations were defined as “community or workplace screening station, outpatient, inpatient, or other.” Categories of medical units where screening and follow-up examination were performed were classified as “outpatient and inpatient”, of which “outpatient” referred to clinics and outpatient departments of hospitals. The definition of family history of CRC was “no, yes, or unknown.” Examination methods were defined as “colonoscopy, double contrast barium enema plus flexible sigmoidoscopy, or others.” Test results were defined as “normal, hemorrhoids, ulcerative colitis, polyp, CRC, or others.” The dependent variable was the mean follow-up time (calculated in days), specifically, the period between the receipt of the positive FOBT result report and the completion of the colonoscopy, double contrast barium enema plus flexible sigmoidoscopy, or other examination method.

Data analysis

Data review. First, "colorectal cancer screening-general information data" in the colorectal cancer screening data (N = 6,117,581) was reviewed to obtain the total number, gender, and year and month of birth of subjects who could undergo the FOBT. The "colorectal cancer screening-FOBT" (N = 5,264,818) data was inspected in terms of gender, screening region, screening location, medical institution code, and family history of colorectal cancer. Missing values and wrongly coded values were checked or deleted. Furthermore, subjects with outpatient visit date and examination date between 2010 and 2013 and those who underwent the first screening were selected as study subjects, and different databases were linked according to the study objective. These databases include "colorectal cancer screening-general information data", "colorectal cancer screening-FOBT," and health resources of medical facilities. After data processing, the total number of cases was 2,488,864. After analysis, general information regarding the 50–75 years old cohort that underwent the first FOBT was obtained. Following that, the data of 191,671 positive cases on screening were inspected and cross-validated with the "colorectal cancer screening-colonoscopy report" (N = 222,683) and health resources of medical facilities. The data was examined for screening criteria and study period (19%), removal of missing and unknown labels (21%), and unreasonable test report date and follow-
up examination date (8.6%). These data were excluded from the study. Finally, 98,482 people with positive FOBT results who underwent follow-up examination were obtained. This data was then analyzed and processed to identify differences in general information and the mean
follow-up time of people with positive FOBT results across different study variables and to analyze factors that affect the mean follow-up time in these people (Fig 1).

**Descriptive statistics.** FOBT result, sex, screening and medical institution region where the follow-up was performed, age at positive result and screening, screening location, medical unit category where screening and follow-up examination was performed, family history of CRC, examination method, diagnosis, and follow-up time are presented as percentage distributions and as means.

**Inferential statistics**

1. Independent sample t test and one-way analysis of variance were used to analyze the sex, hospital region where the follow-up was performed, age, screening location, medical unit category where the follow-up was performed, family history of CRC, examination method, and diagnosis results of the participants to determine whether differences existed in mean follow-up time.

2. Multiple regression analysis was performed to assess the influence of sex, region of the medical institution where the follow-up was performed, age at positive result, screening location, medical unit category where the follow-up was performed, family history of CRC, examination method, and diagnosis results factors affecting the mean follow-up time.

The statistical analysis software used was IBM SPSS Statistics 21.

**Ethics statement**

This study was reviewed and approved by the Institutional Review Board of Antai Medical Care Cooperation Antai Tian-Sheng Memorial Hospital in 2019, and the review number was 19-057-C. The study application for the use of data from the colorectal cancer screening and health resources of medical facilities databases was also approved, and the application number was H108141. The database content in this study was protected by the Personal Data Protection Act and Human Subjects Research Act and have been de-identified and de-linked, coded, and encrypted, which met the FIPS140-2 Level 3 of Federal Information Processing Standard [25].

**Results**

**General information of people aged 50–75 years undergoing the FOBT for the first time**

The results of the descriptive statistical analysis are provided in Table 1. Between 2010 and 2013, a total of 2,488,864 people underwent FOBT for preventive health care, and 191,671 (7.7%) individuals tested positive. Among them, 1,412,702 (56.8%) were women. Regarding the medical institution where the screening was performed, most individuals underwent screening in northern Taiwan, and the least number of people (7,668 people or 0.3%) underwent screening in offshore island cities or counties. The mean age of the individuals who were screened for the first time was 58.9 years. The participants predominantly belonged to the age groups of 51–55 and 56–60 years, accounting for 679,984 people (27.3%) and 660,560 people (26.5%), respectively. Regarding the screening location, most people (1,935,212, 77.8%) were screened as outpatients. As for the medical unit category where the screening was performed, the number of subjects who underwent outpatient testing was 2,436,071 (97.9%), which was higher than that of the inpatient testing. Finally, regarding family history of CRC, most did not report a history (2,269,198, 91.2%).
General information of the population with a positive FOBT result that underwent follow-up examination

The descriptive statistical analysis results are presented in Table 2. From 2010 to 2013, a total of 98,482 people were identified as having positive FOBT results and underwent follow-up examinations. Among them, 53,559 (54.4%) were men. Regarding location, most participants underwent the follow-up in northern Taiwan (42,141, 42.8%), and the least number of participants (273, 0.3%) underwent the follow-up in offshore island cities or counties. Regarding the age of the participants who were found to be positive, the number of people in the age groups of 51–55, 56–60, and 61–65 years were similar, and the number aged 71–75 years was the least at only 5,448 (5.5%). Most people preferred being screened as outpatients in terms of location (79,060, 80.3%). In terms of the choice of medical unit category for follow-up examination, the number of subjects who underwent outpatient follow-up examination was 87,273 (88.6%), which was higher than that of those who underwent inpatient examination. A total of 6,748
people (6.9%) reported a family history of CRC, and most of the participants (92,544, 94.0%) chose colonoscopy, and the least (983, 1.0%) chose double contrast barium enema plus flexible sigmoidoscopy as the follow-up examination method. Most (51,254, 52.0%) were diagnosed as

| Variables | Categories                          | N   | %    | Mean ± SD |
|-----------|------------------------------------|-----|------|-----------|
| Total     |                                    | 98,482 | 100 |           |
| Sex       | Male                               | 53,559 | 54.4 |           |
|           | Female                             | 44,923 | 45.6 |           |
| Medical institution region where the follow-up was performed | Offshore cities and counties | 273 | 0.3 |           |
|           | Northern region                    | 42,141 | 42.8 |           |
|           | Central region                     | 22,091 | 22.4 |           |
|           | Southern region                    | 31,471 | 32.0 |           |
|           | Eastern region                     | 2,506 | 2.5 |           |
| Age tested positive | 50 | 6,206 | 6.3 | 59.99±6.46 |
|           | 51–55                               | 22,415 | 22.8 |           |
|           | 56–60                               | 24,821 | 25.2 |           |
|           | 61–65                               | 23,333 | 23.7 |           |
|           | 66–70                               | 16,259 | 16.5 |           |
|           | 71–75                               | 5,448 | 5.5 |           |
| Screening location | Community or workplace screening station | 16,797 | 17.1 |           |
|           | Outpatient                         | 79,060 | 80.3 |           |
|           | Inpatient                           | 1,467 | 1.5 |           |
|           | Other                               | 1,158 | 1.2 |           |
| Medical unit category where the follow-up examination was performed | Outpatient | 87,273 | 88.6 |           |
|           | Inpatient                           | 11,209 | 11.4 |           |
| Family history of CRC | No | 89,480 | 90.9 |           |
|           | Yes                                 | 6,748 | 6.9 |           |
|           | Unknown                             | 2,254 | 2.3 |           |
| Examination method | Colonoscopy | 92,544 | 94.0 |           |
|           | Double contrast barium enema plus flexible sigmoidoscopy | 983 | 1.0 |           |
|           | Other                               | 4,955 | 5.0 |           |
| Examination result | Normal | 9,955 | 10.1 |           |
|           | Hemorrhoids                         | 28,149 | 28.6 |           |
|           | Ulcerative colitis                  | 530 | 0.5 |           |
|           | Polyp                               | 51,254 | 52.0 |           |
|           | CRC                                 | 4,280 | 4.3 |           |
|           | Other                               | 4,314 | 4.4 |           |
| Follow-up time | Within 30 days | 54,801 | 55.6 |           |
|           | 31–60 days                          | 26,067 | 26.5 |           |
|           | 61–90 days                          | 8,424 | 8.6 |           |
|           | 91 days or longer                   | 9,190 | 9.3 |           |

https://doi.org/10.1371/journal.pone.0258130.t002

Table 2. General information of the population positive for FOBT that underwent follow-up examination.
having polyps, 9,955 (10.1%) were normal, and 4,280 (4.3%) were diagnosed as having CRC. Regarding follow-up time, most (54,801, 55.6%) completed the follow-up within 30 days and 9,190 (9.3%) people underwent the follow-up after 90 days. The mean follow-up time for people who tested positive for FOBT was 41.02 days.

**Differences in mean follow-up time in people with positive FOBT results who have undergone follow-up examination**

Regarding medical institution region where the follow-up was performed, the mean follow-up time for the offshore region was the longest (50.63 days). The mean follow-up time for the five regions exhibited significant differences (p < 0.001). As for age at being tested positive, the mean follow-up time exhibited significant differences among the age groups (p < 0.001). Regarding screening location, inpatients had longer mean follow-up time, and the various categories exhibited significant differences (p < 0.001). With regards to the medical unit category where the follow-up examination was performed, there was a significant difference in mean follow-up time between people with positive FOBT results who underwent outpatient follow-up and those who underwent inpatient follow-up (p < 0.001). Regarding family history of CRC, significant differences were identified in the mean follow-up time among the three categories (p < 0.001). As for follow-up examination methods, the follow-up time for people receiving double contrast barium enema plus flexible sigmoidoscopy was longer (46.94 days), and significant differences were observed in the mean follow-up time among the three methods. Finally, regarding diagnosis results, the mean follow-up time for CRC was 39.25 days, and the mean follow-up time for each category exhibited significant differences (p < 0.001; Table 3).

**Factors affecting the mean follow-up time**

Table 4 presents the model of the mean follow-up time of the participants. After sex was controlled, the mean follow-up time of people who tested positive and whose medical institution where the follow-up was performed was in an offshore island city and county was 10.079 days longer than that in the eastern regions. Further, each age group had a longer mean follow-up time than the age group of 71–75 years. Regarding screening locations, people who tested positive as inpatients had a follow-up time longer by 12.143 days compared to the reference group. With regards to category of the medical unit where the follow-up examination was performed, the mean follow-up time for people with positive FOBT results who underwent inpatient follow-up was 1.257 days shorter than that in those who underwent outpatient follow-up. Compared with that of people not knowing their family history, the mean follow-up time of people with a family history of CRC was 2.562 days shorter. As for the follow-up examination method, people who tested positive and then underwent colonoscopy and those who underwent double contrast barium enema plus flexible sigmoidoscopy had longer mean follow-up time compared with people undergoing other examination methods; their mean follow-up time were 2.488 days and 8.902 days longer, respectively. Regarding diagnosis, people with hemorrhoids or with CRC had shorter mean follow-up time compared with those for people with other results; their times were shorter by 1.578 and 2.476 days, respectively.

**Discussion**

**General information**

The database analysis revealed that the mean age of the people who underwent the FOBT for the first time for preventive health care in Taiwan was 58.9 years, which is higher than the 50
year age limit recommended for cancer screening. Regarding the screening location and category of the medical unit, people who underwent the FOBT tended to be outpatients. As FOBT is a preventive health insurance service in Taiwan, the eligibility of the subject will be noted in the health insurance card. The hospitals or primary care clinics providing FOBT are all under the contract of the National Health Insurance to participate in the colorectal cancer screening

### Table 3. Differences in mean follow-up time in people with positive FOBT results who have undergone follow-up examination.

| Variables                                      | Categories                                      | Mean follow-up period | p-value |
|------------------------------------------------|-------------------------------------------------|-----------------------|---------|
|                                                | Mean ± SD                                      |                       |         |
| **Total**                                      | 98,482                                         |                       |         |
| **Sex**                                        |                                                 |                       |         |
|                                                | Male                                            | 40.96±40.814          |         |
|                                                | Female                                          | 41.08±40.454          | 0.659   |
| **Medical institution region where the follow-up was performed** |                                  |                       |         |
|                                                | Offshore cities and counties                    | 50.63±37.689          |         |
|                                                | Northern region                                | 39.84±38.623          |         |
|                                                | Central region                                 | 39.25±40.550          |         |
|                                                | Southern region                                | 43.70±42.898          |         |
|                                                | Eastern region                                 | 41.60±44.094          | <0.001  |
| **Age tested positive**                        |                                                 |                       |         |
|                                                | 50                                              | 40.38±39.619          |         |
|                                                | 51–55                                           | 40.94±41.067          |         |
|                                                | 56–60                                           | 41.53±41.847          |         |
|                                                | 61–65                                           | 41.35±41.343          |         |
|                                                | 66–70                                           | 41.90±41.455          |         |
|                                                | 71–75                                           | 35.69±26.168          | <0.001  |
| **Screening location**                         |                                                 |                       |         |
|                                                | Community or colon screen stations              | 43.29±41.809          |         |
|                                                | Outpatient                                      | 40.15±39.975          |         |
|                                                | Inpatient                                       | 57.93±50.862          |         |
|                                                | Other                                           | 46.07±47.860          | <0.001  |
| **Medical unit category where the follow-up examination was performed** |                         |                       |         |
|                                                | Outpatient                                      | 41.20±40.515          |         |
|                                                | Inpatient                                       | 39.63±41.661          | <0.001  |
| **Family history of CRC**                      |                                                 |                       |         |
|                                                | No                                              | 41.17±40.934          |         |
|                                                | Yes                                             | 39.04±38.762          |         |
|                                                | Unknown                                         | 40.70±34.192          | <0.001  |
| **Examination method**                         |                                                 |                       |         |
|                                                | Colonoscopy                                     | 41.06±40.597          |         |
|                                                | Double contrast barium enema plus flexible sigmoidoscopy | 46.94±39.887 |         |
|                                                | Other                                           | 39.07±41.652          | <0.001  |
| **Examination result**                         |                                                 |                       |         |
|                                                | Normal                                          | 41.05±39.596          |         |
|                                                | Hemorrhoids                                     | 40.31±40.576          |         |
|                                                | Ulcerative colitis                             | 44.27±43.120          |         |
|                                                | Polyp                                           | 41.49±40.731          |         |
|                                                | CRC                                             | 39.25±40.925          |         |
|                                                | Other                                           | 41.24±41.864          | <0.001  |

https://doi.org/10.1371/journal.pone.0258130.t003
Therefore, when an individual goes for outpatient consultation, the screening status will be indicated in the health care system, and the health care provider will inform the individual regarding the screening information. The health insurance system will also prompt if hospitalized patients meet the screening criteria, and medical staff will carry out screening after considering the patient’s condition and intention. The medical laboratory department in the hospital will process the fecal samples for analysis, whereas clinics will commission medical laboratories for testing. The follow-up of cases with positive FOBT results is the responsibility of case managers in the hospital and nurses in the clinic. In addition, the number of primary clinics has increased from 2010 to 2013, reaching 22,333 in 2018 [28–32], which affects people’s willingness to undergo screening. Therefore, the accessibility and convenience of

Table 4. Factors affecting the mean follow-up time in those who tested positive for FOBT.

| Variables                                         | Categories                        | B     | Standardized coefficients | p-value |
|---------------------------------------------------|-----------------------------------|-------|---------------------------|---------|
| Constant                                          |                                   | 38.936| <0.001                    |         |
| Sex                                               | Male (reference group)            |       |                          |         |
|                                                   | Female                            | 0.279 | 0.003                     | 0.290   |
| Medical institution region where the follow-up was performed | Eastern region (reference group) |       |                          |         |
|                                                   | Offshore cities and counties      | 10.079| 0.013                     | <0.001  |
|                                                   | Northern region                   | −0.605| −0.007                    | 0.471   |
|                                                   | Central region                    | −1.374| −0.014                    | 0.110   |
|                                                   | Southern region                   | 2.932 | 0.034                     | <0.001  |
| Age tested positive                                | 71–75 (reference group)           |       |                          |         |
|                                                   | 50                                | 4.778 | 0.29                      | <0.001  |
|                                                   | 51–55                             | 5.289 | 0.055                     | <0.001  |
|                                                   | 56–60                             | 5.831 | 0.062                     | <0.001  |
|                                                   | 61–65                             | 5.554 | 0.058                     | <0.001  |
|                                                   | 66–70                             | 6.082 | 0.056                     | <0.001  |
| Screening location                                 | Other (reference group)           |       |                          |         |
|                                                   | Community or workplace screening station | −2.675| −0.025                    | 0.030   |
|                                                   | Outpatient                        | −5.355| −0.052                    | <0.001  |
|                                                   | Inpatient                         | 12.143| 0.036                     | <0.001  |
| Category of the medical unit where the follow-up examination was performed | Outpatient (reference group)      |       |                          |         |
|                                                   | Inpatient                         | -1.257| -0.010                    | <0.002  |
| Family history of CRC                             | Unknown (reference group)         |       |                          |         |
|                                                   | No                                | −0.579| −0.004                    | 0.509   |
|                                                   | Yes                               | −2.562| −0.016                    | 0.010   |
| Examination method                                 | Other (reference group)           |       |                          |         |
|                                                   | Colonoscopy                       | 2.488 | 0.015                     | <0.001  |
|                                                   | Double contrast barium enema plus flexible sigmoidoscopy | 8.902 | 0.022                     | <0.001  |
| Examination result                                 | Other (reference group)           |       |                          |         |
|                                                   | Normal                            | −0.477| −0.004                    | 0.522   |
|                                                   | Hemorrhoids                       | −1.578| −0.018                    | 0.022   |
|                                                   | Ulcerative colitis                | 2.452 | 0.004                     | 0.191   |
|                                                   | Polyp                             | −0.294| −0.004                    | 0.664   |
|                                                   | CRC                               | −2.476| −0.012                    | 0.006   |

R² = 0.008, Adjusted R² = 0.007.

https://doi.org/10.1371/journal.pone.0258130.t004
qualified clinics has made them the location of choice for screening for many people. Moreover, health units in each administrative region cooperate with local medical institutions and go to communities or workplaces to offer cancer screening services to facilitate the testing of community dwellers and working people (Table 1). The number of people who tested positive for FOBT and underwent a follow-up examination was 98,482. The numbers of men and women were similar. The age of the participants was concentrated between 51 and 65 years, and most did not have a family history of CRC, which was similar to the results of relevant studies [33,34]. Most of the institutions that the participants went to were in metropolitan areas, such as the northern, central, and southern regions; this was possibly affected by the distribution of medical resources and education level [9,27]. The follow-up examination method most people underwent was colonoscopy. If patients test positive for FOBT, the patient should be followed up by the physicians belonging to the departments of colon and rectal surgery, endoscopy, gastrointestinal internal medicine, or general surgery to understand the cause of the FOBT for positive [8,15]. The standard, comprehensive recheck methods are colonoscopy or double contrast barium enema plus flexible sigmoidoscopy [8,15,35]. Most people were diagnosed as having polyps or hemorrhoids; 4.3% had CRC. Clearly, among this group, a follow-up examination can detect colorectal-related symptoms and enable early treatment. In this study, the mean follow-up time for people who tested positive was 41.02 days. Approximately 82% of people completed the follow-up within 60 days. Another study suggested that the mean follow-up duration should be within 90 days but discovered it to be 112 days [9]. Other studies have found that the mean waiting period between the positive FOBT result and colonoscopy was 105–202 days [36,37]. In this study, 88.6% of people with positive FOBT results underwent follow-up examination in outpatient clinics and 95% underwent colonoscopy or double contrast barium enema plus flexible sigmoidoscopy. This is due to a well-established colorectal cancer screening program that includes determination of a FOBT screening group, wide availability of screening sites, actively contact of positive individuals, and high accessibility to specialty care and follow-up [8,15,28–32]. Relevant studies have shown that approximately 25%–59% of people complete examinations, such as colonoscopy or double contrast barium enema plus flexible sigmoidoscopy, in the 1-year follow-up period [8,35,38], which suggests that Taiwan has a favorable result for the follow-up examinations after a positive CRC screening result (Table 2).

Differences in mean follow-up time

A study revealed that among people who tested positive for FOBT, approximately half had a follow-up time affected by medical institutional factors [9]. In this study, the longer mean follow-up time of offshore cities and counties is likely a result of less medical resource allocation [27]. The mean number of days to follow-up examination for each age group was approximately 40. However, the mean number of days to follow-up examination for the group aged 71–75 years was 35 days as most people in this age group are retired and can easily arrange a time to undergo colonoscopy after conversing with medical personnel. In contrast, people of other age groups may be working and may be unable to easily arrange a time for undergoing the procedure. Regarding screening location, inpatients had a longer mean follow-up time compared to the reference group, possibly because they were in the hospital because of other illnesses and could not immediately undergo colonoscopy. In terms of the category of the medical units performing follow-up examination, those with positive FOBT results will be evaluated by an outpatient specialist and will be asked to undergo colonoscopy, with confirmed dietary control and purgative administration prior to the test [8,15], so that colonoscopy can be performed on the day of the appointment in the outpatient clinic. Therefore, the
time from notification of positive FOBT results to the completion of follow-up examination is long [9,36,37]. For inpatients with positive FOBT results, the physician will consider their condition and adopt examination methods with lower risk [15]. In addition, when inpatients test positive for FOBT, the physician will evaluate and arrange for follow-up examination, where it can be reserved on the day of examination to reduce the waiting time. Therefore, the follow-up time for inpatients with positive FOBT results is shorter than that for the outpatients. Analysis in terms of family history of CRC revealed that positive cases with a family history of CRC had a shorter mean follow-up time compared with its two other counterparts possibly because they had knowledge about the disease and were more proactive in subsequent follow-ups. Regarding examination methods, Taiwan adopts double contrast barium enema plus flexible sigmoidoscopy as the assistive examination method for people who cannot undergo colonoscopy. In implementation, both items must be conducted to be considered a comprehensive colorectal test [8]. Therefore, the mean follow-up time for double contrast barium enema plus flexible sigmoidoscopy was longer. The mean follow-up time for those with positive screening for FOBT varied significantly among diagnoses, and related studies show that there is effective control of the follow-up time for those with positive screening results for FOBT [18–20]. In this study, location of the institution where the follow-up examination was performed, age, screening location, category of follow-up institution, family history, follow-up examination method, and diagnosis all exhibited significant differences in mean follow-up time (Table 3). Relevant studies have discovered that medical resources and health care system, patient factors, screening process and cancer diagnosis method, and health policies may affect the willingness of 40%–85% people who test positive for FOBT to undergo a follow-up examination [9,19,21,39,40].

Factors affecting mean follow-up time

Factors affecting the mean follow-up time of the participants consisted of the region of the follow-up examination institution, age, screening location, category of the medical unit where follow-up examination was performed, family history, examination method, and diagnosis (Table 4). In offshore cities and counties where medical resources were scarce, follow-up examinations were delayed. Compared with the eastern region, people in the southern region waited 2.932 days longer. According to the Yearbook of Manpower Survey Statistics of 2013, more people in the southern region aged 50 years or over work than do their counterparts in the eastern, central, and northern regions [41]. Related studies showed that there was no significant correlation between the socioeconomic status of those who screened positive for FOBT and those who underwent follow-up examination, but there was a significant increase in compliance with follow-up testing among those with higher socioeconomic status [9]. The results of another study showed that people with low socioeconomic status face a large number of obstacles in undergoing colonoscopy examinations, including pre-examination dietary management, purgative administration, withdrawal of anticoagulants, leave application, and job nature [8,15,42,43], which also indirectly affects the willingness of the working class to undergo follow-up examinations. With regards to age, the mean follow-up time in people with positive FOBT results aged 50–70 years was higher than that of the reference group. A related study showed that the ratio of people with positive FOBT results who undergo follow-up examination is higher in those aged 50–59 and 70–75 years [9]. In Taiwan, 2,523‰ and 219‰ of the working population are aged 50–64 and >65 years, respectively [41]. With regards to scheduling for undergoing colonoscopy, the group aged 50–70 years who may are still working need to consider pre-examination preparation time and the nature of their work compared with the group aged 71–75 years who may are not working [8,15,42,43], which may lead to a
longer follow-up time. As for screening location, people who test positive in a community or workplace screening station or in an outpatient setting are less likely to have a severe illness; thus, arranging for colonoscopy for them is easy. In contrast, most inpatients have diseases or may have conditions with high severity. As a result, arranging colonoscopy requires the assessment of their disease and related factors, and hence, their mean follow-up time may be lengthier compared to the reference group. With regard to the category of the medical unit where follow-up examination was performed, after a physician has confirmed that an inpatient with positive FOBT results can undergo follow-up examination, an auxiliary examination with lower risk, such as double contrast barium enema or flexible sigmoidoscopy, may sometimes be selected to decrease examination inconvenience [15]. In addition, this can decrease the waiting time. Therefore, the waiting time for inpatients with positive FOBT results is lower than that of the outpatients. As for family history of CRC, people with a family history who tested positive were proactive in receiving follow-up examinations, and their follow-up time was short. Regarding examination method, currently, colonoscopy is the most comprehensive examination tool [8,15,35]. Therefore, after evaluation, most physicians will recommend undergoing colonoscopy or double contrast barium enema plus flexible sigmoidoscopy. As these cases require dietary control and bowel cleansing medication prior to screening [8,15], there is a long pre-procedure period. Moreover, double contrast barium enema plus flexible sigmoidoscopy can be performed on different dates and the date of the final examination is defined as the follow-up completion date. Therefore, the follow-up time is longer. Other examinations will usually employ flexible sigmoidoscopy or double contrast barium enema alone as alternative methods. Flexible sigmoidoscopy can be immediately performed after an enema; however, the purgative should be drunk in advance for double contrast barium enema [15]. Therefore, comprehensive colon examination methods have a longer follow-up time than that of the other examination methods. The diagnosis results indicating hemorrhoids or CRC had shorter mean follow-up time, revealing that relevant colorectal diseases and cancer can be targeted for early treatment through screening, follow-up, and diagnosis. Empirical data indicate that CRC is a type of cancer that can be detected and treated in its early stage through preliminary screening and the discovery of abnormalities. When it is discovered early, people with CRC who undergo proactive treatment have a 90% survival rate. In contrast, only 10% of people with late stages of CRC have a 5-year survival rate [9,44,45].

To summarize, the follow-up time of people who tested positive for FOBT was related to disease development. A relevant study reported that, compared with people who underwent colonoscopy 8–30 days after they tested positive, people who underwent it within 6 months of testing positive did not have an increased risk for diseases related to CRC. However, people whose follow-up period exceeded 6 months had an increased risk for stage II CRC. For people whose follow-up time reached 12 months, their disease evolved into stage II–IV CRC and they also developed other related diseases [18]. Factors affecting the follow-up time include age, sex, ethnicity, personal health cognition, health education, follow-up method, the degree of physician intervention, and health policy [9,21,22,46–48].

The CRC screening database was collected and established by the public sector; thus, the data samples are credible and representative. However, the analysis of the secondary database has limitations. (1) This study lacked detailed personal health information on the screened population. Cancer screening behavior and disease follow-up examination involve multiple factors, such as educational level, socioeconomic background, marital status, dietary habit, exercise frequency, and whether one undergoes regular health examinations. These data cannot be obtained from the database; therefore, the research on relevant topics was limited. (2) Information in the “other” columns was unclear. Some of the research variables had the option of “other,” without supplementary descriptions, resulting in the loss of relevant data. (3)
Specific disease data was lacking. The database did not have relevant information for disease groups, such as whether CRC was present before the screening and whether other types of cancer or other chronic diseases were present that may have led to the overestimation of cases positive for CRC. In addition, the colorectal cancer screening database has been recently established, and some of the fields are still undergoing follow-up and compiling. For example, undisplayed gender, missing date, wrong code, and omission of screening or follow-up institution can lead to underestimation of screening cases.

Conclusions

The results of this study indicate that factors affecting the follow-up time of people who tested positive in the FOBT results were the region and category of the follow-up medical unit, age, screening location, family history, examination method, and diagnosis results. We believe that screening is most essential for cancer prevention. However, to date, the establishment and implementation of relevant policies for cancer prevention generally require medical personnel to take the initiative. In the future, people’s cognition and knowledge and their capability in personal cancer prevention should be increased, and they should reinforce self-health management. Therefore, to ensure screening at the appropriate age and to construct a comprehensive follow-up network, popularizing health education and having sufficient diagnosis tools are crucial in CRC prevention policies. The results of this study may serve as a reference for future studies on reducing the follow-up time of people who test positive for FOBT.

Acknowledgments

The researchers are grateful to the Health and Welfare Data Science Center of the Ministry of Health and Welfare and the Center for Medical Informatics and Statistics for reviewing and approving the data application for the study and for offering a location for data analysis. The researchers are also grateful for the useful suggestions provided by the journal editors and reviewers.

Author Contributions

Conceptualization: Yin-Wen Cheng, Ying-Chun Li.
Data curation: Yin-Wen Cheng.
Formal analysis: Yin-Wen Cheng.
Funding acquisition: Yin-Wen Cheng.
Methodology: Yin-Wen Cheng, Ying-Chun Li.
Project administration: Yin-Wen Cheng.
Resources: Yin-Wen Cheng, Ying-Chun Li.
Supervision: Ying-Chun Li.
Writing – original draft: Yin-Wen Cheng.
Writing – review & editing: Ying-Chun Li.

References

1. Ministry of Health and Welfare, R.O.C. (Taiwan). Death Statistics. 2018 [cited 2021 Jan 17]. Available from: https://dep.mohw.gov.tw/DOS/lp-4472-113.html.
2. Health Promotion Administration, Ministry of Health and Welfare, R.O.C. (Taiwan). Cancer Registration Annual Report. 2018 [cited 2021 Jan 17]. Available from: https://www.hpa.gov.tw/Pages/List.aspx?nodeid=269.

3. Global Cancer Observatory (GCO). Cancer Today. 2020 [cited 2021 Jan 21]. Available from: http://gco.iarc.fr/today/home.

4. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017; 66(4):683–691. https://doi.org/10.1136/gutjnl-2015-310912 PMID: 26869801

5. Takahashi Y, Sugimachi K, Yamamoto K, Niida A, Shimamura T, Sato T, et al. Japanese genome-wide association study identifies a significant colorectal cancer susceptibility locus at chromosome 10p14. Cancer Sci. 2017; 108(11):2239–2247. https://doi.org/10.1111/cas.13391 PMID: 28869801

6. Tanskanen T, van den Berg L, Välimäki N, Aavikko M, Ness-Jensen E, Hveem K, et al. Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci. Int J Cancer. 2018; 142(3):540–546. https://doi.org/10.1002/ijc.31076 PMID: 28960316

7. Lows & Regulations Database of the Republic of China. Cancer Control Act. 2018 [cited 2021 Jan 17]. Available from: https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0070008.

8. Wang YW, Chen HH, Wu MS, Chiu HM. Taiwanese Nationwide Colorectal Cancer Screening Program. Current status and future challenge of population-based organized colorectal cancer screening: Lesson from the first decade of Taiwanese program. J Formos Med Assoc. 2018; 117(5):358–364. https://doi.org/10.1016/j.jfma.2017.09.010 PMID: 28988890

9. Azulay R, Valinsky L, Hershkowitz F, Magnezi R. Repeated automated mobile text messaging reminders for follow-up of positive fecal occult blood tests: Randomized controlled trial. JMIR Mhealth Uhealth. 2019; 7(2):e11114. https://doi.org/10.2196/11114 PMID: 30720439

10. Douma LN, Ulters E, Timmermans DRM. Why are the public so positive about colorectal cancer screening? BMC Public Health. 2018; 18(1):1212. https://doi.org/10.1186/s12889-018-6106-1 PMID: 30376841

11. Hansen AT, Hoffmann-Lücke E, Nielsen BK, Reinholdt B, Hindersson P, Heidemann K, et al. Delayed sample arrival at the laboratory does not lead to more false negatives in the Danish population screening for colorectal cancer. Scand J Clin Lab Invest. 2017; 77(8):685–688. https://doi.org/10.1080/00365513.2017.1379091 PMID: 28933963

12. Young GP, Rabeneck L, Winawer SJ. The global paradigm shift in screening for colorectal cancer. Gastroenterology. 2019; 156(4):843–851.e2. https://doi.org/10.1053/j.gastro.2019.02.006 PMID: 30776340

13. Saito H, Soma Y, Koeda J, Wada T, Kawaguchi H, Sobue T, et al. Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochromatographic test. A case-control study. Int J Cancer. 1995; 61(4):465–469. https://doi.org/10.1002/ijc.2910610406 PMID: 7759151

14. Young GP, Cole SR. Which fecal occult blood test is best to screen for colorectal cancer? Nat Clin Pract Gastroenterol Hepatol. 2009; 6(3):140–141. https://doi.org/10.1038/ncpgasthep1358 PMID: 19174764

15. Chiu HM. Essential Knowledge on for Bowel Activity: Colorectal Cancer is 90% Treatable when detected early! Effective interventions to Prevent Colorectal Cancer. Taipei: Commonwealth Publishing Group; 2017.

16. Singh H, Kadiyala H, Bhagwath G, Shethia A, El-Serag H, Walder A, et al. Using a multifaceted approach to improve the follow-up of positive fecal occult blood test results. Am J Gastroenterol. 2009; 104(4):942–952. https://doi.org/10.1038/ajg.2009.55 PMID: 19293786

17. Meester RG, Zauber AG, Doubeni CA, Jensen CD, Quinn VP, Helfand M, et al. Consequences of increasing time to colonoscopy examination after positive result from fecal colorectal cancer screening test. Clin Gastroenterol Hepatol. 2016; 14(10):1445–1451.e8. https://doi.org/10.1016/j.cgh.2016.05.017 PMID: 27211498

18. Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Association between time to colonoscopy after a positive fecal test result and risk of colorectal cancer and cancer stage at diagnosis. JAMA. 2017; 317(16):1631–1641. https://doi.org/10.1001/jama.2017.3634 PMID: 28444278

19. Partin MR, Burgess DJ, Burgess JF Jr, Gravely A, Haggstrom D, Lillie SE, et al. Organizational predictors of colonoscopy follow-up for positive fecal occult blood test results: an observational study. Cancer Epidemiol Biomarkers Prev. 2015; 24(2):422–434. https://doi.org/10.1158/1055-9965.EPI-14-1170 PMID: 25471345

20. Chubak J, Garcia MP, Burnett-Hartman AN, Zheng Y, Corley DA, Halm EA, et al. Time to colonoscopy after positive fecal blood test in four US health care systems. Cancer Epidemiol Biomarkers Prev. 2016; 25(2):344–350. https://doi.org/10.1158/1055-9965.EPI-15-0470 PMID: 26843920
21. McCarthy AM, Kim JJ, Beaber EF, Zheng Y, Burnett-Hartman A, Chubak J, et al. Follow-Up of abnormal breast and colorectal cancer screening by race/ethnicity. Am J Prev Med. 2016; 51(4):507–512. https://doi.org/10.1016/j.amepre.2016.03.017 PMID: 27132628

22. Oluloro A, Petrlik AF, Turner A, Kapka T, Rivelli J, Carney PA, et al. Timeliness of colonoscopy after abnormal fecal test results in a safety net practice. J Community Health. 2016; 41(4):864–870. https://doi.org/10.1007/s10900-016-0165-y PMID: 26874943

23. Atinafu BT, Bulti FA, Demelew TM. Survival status and predictors of mortality among colorectal cancer patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: a retrospective follow up study. J Cancer Prev. 2020; 25(1):38–47. https://doi.org/10.15430/JCP.2020.25.1.38 PMID: 32266178

24. Su SY, Huang JY. Effect of nationwide screening program on colorectal cancer mortality in Taiwan: A controlled interrupted time series analysis. Int J Colorectal Dis. 2020; 35(2):239–247. https://doi.org/10.1007/s00384-019-03468-y PMID: 31834474

25. Health and Welfare Data Science Center, Ministry of Health and Welfare, R.O.C. (Taiwan). Colorectal Cancer Screening (Health-55: H_BHP_CCS). 2019 [cited 2021 Jan 17]. Available from: https://dep.mohw.gov.tw/DOS/lp-3147-113-3-20.html.

26. Health and Welfare Data Science Center, Ministry of Health and Welfare, R.O.C. (Taiwan). Health Resources of Medical Facilities (H_OST_ResMF). 2020 [cited 2021 Jan 17]. Available from: https://dep.mohw.gov.tw/DOS/lp-3147-113.html.

27. National Development Council, R.O.C. (Taiwan). Urban and Regional Development Statistics. 2013 [cited 2021 Jan 21]. Available from: https://www.ndc.gov.tw/en/News_Content.aspx?n=AC1FC9C868FAE2E2D&amp;sms=F7E3808BEC35F3&amp;s=E6CE6ED9A99DB123.

28. Ministry of Health and Welfare, R.O.C. (Taiwan). Current Status of Medical Institutions and Statistics of Hospital Medical Services. 2010 [cited 2021 Jan 17]. Available from: https://dep.mohw.gov.tw/DOS/np-1865-113.html.

29. Ministry of Health and Welfare, R.O.C. (Taiwan). Current Status of Medical Institutions and Statistics of Hospital Medical Services. 2011 [cited 2021 Jan 17]. Available from: https://dep.mohw.gov.tw/DOS/np-1865-113.html.

30. Ministry of Health and Welfare, R.O.C. (Taiwan). Current Status of Medical Institutions and Statistics of Hospital Medical Services. 2012 [cited 2021 Jan 17] Available from: https://dep.mohw.gov.tw/DOS/np-1865-113.html.

31. Ministry of Health and Welfare, R.O.C. (Taiwan). Current Status of Medical Institutions and Statistics of Hospital Medical Services. 2013 [cited 2021 Jan 17]. Available from: https://dep.mohw.gov.tw/DOS/np-1865-113.html.

32. Ministry of Health and Welfare, R.O.C. (Taiwan). Current Status of Medical Institutions and Statistics of Hospital Medical Services. 2018 [cited 2021 Jan 17]. Available from: https://dep.mohw.gov.tw/DOS/np-1865-113.html.

33. Changchien CR. Epidemiology of colorectal cancer in Taiwan. J Chinese Oncol Soc. 2008; 24(3):143–147. https://doi.org/10.1022/bjs.5786 PMID: 18064717

34. Zhiqiang F, Jie C, Yuqiang N, Chenghua G, Hong W, Zheng S, et al. Analysis of population-based colorectal cancer screening in Guangzhou, 2011–2015. Cancer Med. 2019; 8(5):2496–2502. https://doi.org/10.1002/cam4.1867 PMID: 30927329

35. Etzioni DA, Yano EM, Rubenstein LV, Lee ML, Ko CY, Brook RH, et al. Measuring the quality of colorectal cancer screening: the importance of follow-up. Dis Colon Rectum. 2006; 49(7):1002–1010. https://doi.org/10.1007/s10350-006-0533-2 PMID: 16673056

36. Paszat L, Rabeneck L, Kiefert L, Mai V, Ritvo P, Sullivan T. Endoscopic follow-up of positive fecal occult blood testing in the Ontario FOBT Project. Can J Gastroenterol. 2007; 21(6):379–382. https://doi.org/10.1155/2007/006-0533-2 PMID: 17571172

37. Leddin D, Armstrong D, Borgiaonkar M, Bridges RJ, Fallone CA, Telford JJ, et al. The 2012 SAGE wait times program: survey of access to gastroenterology in Canada. Can J Gastroenterol. 2013; 27(2):83–89. https://doi.org/10.1155/2013/143018 PMID: 23472243

38. Myers RE, Turner B, Weinberg D, Hyslop T, Hauck WW, Brigham T, et al. Impact of a physician-oriented intervention on follow-up in colorectal cancer screening. Prev Med. 2004; 38(4):375–381. https://doi.org/10.1016/j.ypmed.2003.11.010 PMID: 15020170

39. Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, et al. Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care. 2008; 46(Suppl 1):S91–S96. https://doi.org/10.1097/MLR.0b013e31817946c8 PMID: 18725839

40. Humphrey LL, Shannon J, Partin MR, O’Malley J, Chen Z, Helfand M. Improving the follow-up of positive hemoccult screening tests: an electronic intervention. J Gen Intern Med. 2011; 26(7):691–697. https://doi.org/10.1007/s11606-011-1639-3 PMID: 21327529
41. Directorate-General of Budget, Accounting and Statistics, Executive Yuan, R.O.C. (Taiwan). Yearbook of Manpower Survey Statistics. 2013 [cited 2021 Jan 21]. Available from: https://ebook.dgbas.gov.tw/ct.asp?xItem=35847&ctNode=5971&mp=103.

42. Doubeni CA, Laiyemo AO, Reed G, Field TS, Fletcher RH. Socioeconomic and racial patterns of colorectal cancer screening among Medicare enrollees in 2000 to 2005. Cancer Epidemiol Biomarkers Prev. 2009; 18(8):2170–2175. https://doi.org/10.1158/1055-9965.EPI-09-0104 PMID: 19622721

43. Warren Andersen S, Blot WJ, Lipworth L, Steinwandel M, Murff HJ, Zheng W. Association of race and socioeconomic status with colorectal cancer screening, colorectal cancer risk, and mortality in Southern US adults. JAMA Netw Open. 2019; 2(12): e1917995. https://doi.org/10.1001/jamanetworkopen.2019.17995 PMID: 31860105

44. Tseng CC, Lee CL, Wu CH. Screening and surveillance of colorectal neoplasms—review and update of guidelines. J Intern Med Taiwan. 2009; 20(6):506–513. https://doi.org/10.6314/JIMT.2009.20(6).05

45. Ou CH, Yu FJ, Hsu WH, Wang SW, Wu DC, Hu HM. Current implementation status of colorectal cancer screening and monitoring in Taiwan. Taiwan Med J. 2012; 55(3):17–20. https://doi.org/10.30044/TMJ.201203.0003

46. Amlani B, Radaelli F, Bhandari P. A survey on colonoscopy shows poor understanding of its protective value and widespread misconceptions across Europe. PLoS ONE. 2020; 15(5):e0233490. https://doi.org/10.1371/journal.pone.0233490 PMID: 32437402

47. Singal AG, Gupta S, Skinner CS, Ahn C, Santini NO, Agrawal D, et al. Effect of colonoscopy outreach vs fecal immunochemical test outreach on colorectal cancer screening completion: A randomized clinical trial. JAMA. 2017; 18(9):806–815. https://doi.org/10.1001/jama.2017.11389 PMID: 28873161

48. Stock C, Hoffmeister M, Birken B, Brenner H. Inter-physician variation in follow-up colonoscopies after screening colonoscopy. PLoS ONE. 2013; 8(7):e69312. https://doi.org/10.1371/journal.pone.0069312 PMID: 23874941